SARS‐CoV‐2 infection results in a mild‐to‐moderate disease course in most patients, allowing outpatient self‐care and quarantine. However, in ≈10% of cases a two‐ or three‐phasic critical disease course with starting from day 7 to 10 is observed. To facilitate and plan outpatient care, biomarkers prognosing such worsening at an early stage appear of outmost importance. In this accelerated article, the identification of urinary peptides significantly associated with SARS‐CoV‐2 infection, and the development of a multi‐marker urinary peptide based test, COVID20, that may enable prognosis of critical and fatal outcomes in COVID‐19 patients is reported. COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity. Based on the performance in this pilot study, testing in a prospective study on 1000 patients has been initiated.

中文翻译：

---

泌尿蛋白质组学与COVID-19严重性关联：原理性证明数据和多中心诊断研究的设计。

在大多数患者中，SARS-CoV-2感染会导致轻度至中度的病程，从而允许门诊患者进行自我护理和隔离。但是，在大约10％的病例中，观察到从第7天到第10天开始的两阶段或三阶段严重疾病过程。为了促进和计划门诊护理，在早期阶段对这种恶化进行预后的生物标志物显得尤为重要。在本加速文章中，鉴定与SARS-CoV-2感染显着相关的尿肽，以及开发基于多标记尿肽的测试COVID20，该测试可预示COVID-19患者的关键和致命结果报告。COVID20由20种内源性肽组成，这些肽主要衍生自各种胶原蛋白链，能够以100％的特异性以83％的敏感性将中度或重度疾病与临界状态或死亡区分开来。根据这项先导研究的表现，已开始对1000名患者进行前瞻性测试。